Cefdinir

From Wikipedia, the free encyclopedia - View original article

Cefdinir
Cefdinir.svg
Systematic (IUPAC) name
8-[2-(2-amino-1,3-thiazol-4-yl)-1-hydroxy-2-nitroso-
ethenyl]amino-4-ethenyl-7-oxo-2-thia-6-
azabicyclo[4.2.0]oct-4-ene-5-carboxylic acid
Clinical data
Trade namesCefzon
AHFS/Drugs.commonograph
MedlinePlusa698001
Pregnancy cat.B (US)
Legal statusRx only (US)
RoutesOral
Pharmacokinetic data
Bioavailability16% to 21% (dose-dependent)
Protein binding60% to 70%
MetabolismNegligible
Half-life1.7 ± 0.6 hours
ExcretionRenal
Identifiers
CAS number91832-40-5 YesY
ATC codeJ01DD15
PubChemCID 6915944
DrugBankDB00535
ChemSpider5291705 YesY
UNIICI0FAO63WC YesY
KEGGD00917 YesY
ChEBICHEBI:3485 YesY
ChEMBLCHEMBL927 YesY
Chemical data
FormulaC14H13N5O5S2 
Mol. mass395.416 g/mol
 YesY (what is this?)  (verify)
 
Jump to: navigation, search
Cefdinir
Cefdinir.svg
Systematic (IUPAC) name
8-[2-(2-amino-1,3-thiazol-4-yl)-1-hydroxy-2-nitroso-
ethenyl]amino-4-ethenyl-7-oxo-2-thia-6-
azabicyclo[4.2.0]oct-4-ene-5-carboxylic acid
Clinical data
Trade namesCefzon
AHFS/Drugs.commonograph
MedlinePlusa698001
Pregnancy cat.B (US)
Legal statusRx only (US)
RoutesOral
Pharmacokinetic data
Bioavailability16% to 21% (dose-dependent)
Protein binding60% to 70%
MetabolismNegligible
Half-life1.7 ± 0.6 hours
ExcretionRenal
Identifiers
CAS number91832-40-5 YesY
ATC codeJ01DD15
PubChemCID 6915944
DrugBankDB00535
ChemSpider5291705 YesY
UNIICI0FAO63WC YesY
KEGGD00917 YesY
ChEBICHEBI:3485 YesY
ChEMBLCHEMBL927 YesY
Chemical data
FormulaC14H13N5O5S2 
Mol. mass395.416 g/mol
 YesY (what is this?)  (verify)

Cefdinir is a third generation oral cephalosporin antibiotic. It was discovered by Fujisawa Pharmaceutical Co., Ltd. "Fujisawa" (now Astellas) and introduced in 1991 under the brand name Cefzon.[1][2] Warner-Lambert licensed this cephalosporin, cefdinir, for marketing in US from Fujisawa, Japan.[3] Abbott obtained U.S. marketing rights to Omnicef (Cefdinir) in December 1998 through an agreement with Warner-Lambert Company.[4] It was approved by FDA on Dec 4, 1997.[5] It is available in US as Omnicef by Abbott Laboratories and in India as Cednir by Abbott, Kefnir by Glenmark and Cefdiel by Ranbaxy.

As of 2008, cefdinir was the highest-selling cephalosporin antibiotic in the United States, with more than US$585 million in retail sales of its generic versions alone.[6]

Mechanism of action[edit]

Indications[edit]

Therapeutic uses of cefdinir include otitis media, soft tissue infections, and respiratory tract infections, including sinusitis, strep throat, community-acquired pneumonia and acute exacerbations of bronchitis.

Susceptible organisms[edit]

Cefdinir is a bacteriocidal antibiotic. It can be used to treat infections caused by several Gram-negative and Gram-positive bacteria.

Spectrum of bacterial susceptibility and resistance[edit]

Cefdinir is a broad spectrum antibiotic and has been used to treat infections of the respiratory tract including pneumonia, sinusitis, and bronchitis. The following represents MIC susceptibility data for a few medically significant microorganisms.

[7]

Side effects[edit]

Side effects include diarrhea, vaginal infections or inflammation, nausea, headache, and abdominal pain."[8]

Available forms[edit]

Cefdinir is administered orally. It is available as capsules and a suspension. Dosage, schedule, and duration of therapy varies according to the type of infection.

"Blood" in the stool[edit]

The pediatric version of cefdinir can bind to iron in the digestive tract; in rare cases, this causes a rust or red discoloration of the stool. Blood typically appears dark brown or black in stool, and testing may confirm which is present.

If the reddish stool is accompanied by abdominal pain, weight loss, diarrhea, etc., a Clostridium difficile infection caused by the antibiotic could be signified.

Special caution required for pediatric dry powder: Dry powder may take longer for proper mixing

References[edit]

External links[edit]